Company Analysis Gilead Sciences
1. Summary
Advantages
- Dividends (4.09%) are higher than the sector average (0.5473%).
- The stock's return over the last year (4.05%) is higher than the sector average (-31.05%).
- The company's current efficiency (ROE=24.9%) is higher than the sector average (ROE=9.61%)
Disadvantages
- Price (89.88 $) is higher than fair price (52.68 $)
- Current debt level 40.22% has increased over 5 years from 39.9%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
18 november 17:19 COVID-19 vaccine start-up files for IPO
18 november 16:26 Inside the race for a COVID-19 treatment pill
2.3. Market efficiency
| Gilead Sciences | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.5% | -22.6% | 2.7% |
| 90 days | 5.7% | -35.5% | 7.7% |
| 1 year | 4.1% | -31% | 29.1% |
GILD vs Sector: Gilead Sciences has outperformed the "Healthcare" sector by 35.1% over the past year.
GILD vs Market: Gilead Sciences has significantly underperformed the market by -25% over the past year.
Stable price: GILD is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GILD with weekly volatility of 0.0779% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (89.88 $) is higher than the fair price (52.68 $).
Price is higher than fair: The current price (89.88 $) is 41.4% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (17.69) is lower than that of the sector as a whole (48.72).
P/E vs Market: The company's P/E (17.69) is lower than that of the market as a whole (49.05).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.41) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (4.41) is higher than that of the market as a whole (3.18).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.7) is lower than that of the sector as a whole (33.75).
P/S vs Market: The company's P/S indicator (3.7) is lower than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (15.66) is higher than that of the sector as a whole (-22.17).
EV/Ebitda vs Market: The company's EV/Ebitda (15.66) is lower than that of the market as a whole (28.35).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 1253.03% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (1253.03%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (123.79%).
5.4. ROE
ROE vs Sector: The company's ROE (24.9%) is higher than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (24.9%) is higher than that of the market as a whole (10.67%).
5.5. ROA
ROA vs Sector: The company's ROA (9.12%) is higher than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (9.12%) is higher than that of the market as a whole (6.44%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (11.06%) is higher than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (11.06%) is higher than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 4.09% is higher than the average for the sector '0.5473%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 4.09% has been steadily paid over the past 7 years, DSI=1.
Dividend growth: Company's dividend yield 4.09% has been growing over the last 5 years. Growth over 13 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (67.24%) are at a comfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 55.02% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 15.01.2025 | Dickinson Andrew D Chief Financial Officer |
Sale | 91.35 | 228 375 | 2 500 |
| 19.12.2024 | GILEAD SCIENCES, INC. 10% Owner |
Purchase | 21.37 | 20 098 500 | 940 499 |
| 29.11.2024 | Dickinson Andrew D Chief Financial Officer |
Sale | 92.76 | 23 064 300 | 248 645 |
| 29.11.2024 | Dickinson Andrew D Chief Financial Officer |
Purchase | 70.5 | 17 529 500 | 248 645 |
| 29.11.2024 | ANDREW DICKINSON Officer |
Purchase | 92.76 | 23 064 300 | 248 645 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
